668455-23-0Relevant academic research and scientific papers
Discovery of (2R)-2-(3-{3-[(4-methoxyphenyl)carbonyl]-2-methyl-6- (trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): A novel selective peroxisome proliferator-activated receptor γ modulator for the treatment of type 2 diabetes mellitus with
Acton III, John J.,Akiyama, Taro E.,Chang, Ching H.,Colwell, Lawrence,Debenham, Sheryl,Doebber, Thomas,Einstein, Monica,Liu, Kun,McCann, Margaret E.,Moller, David E.,Muise, Eric S.,Tan, Yugen,Thompson, John R.,Wong, Kenny K.,Wu, Margaret,Xu, Libo,Meinke, Peter T.,Berger, Joel P.,Wood, Harold B.
experimental part, p. 3846 - 3854 (2010/03/01)
Peroxisome proliferator-activated receptor gamma (PPARγ) agonists are used to treat type 2 diabetes mellitus (T2DM). Widespread use of PPARγ agonists has been prevented due to adverse effects including weight gain, edema, and increased risk of congestive
INDOLES HAVING ANTI-DIABETIC ACTIVITY
-
Page/Page column 25, (2008/06/13)
Indoles of Formula (I) having -X-aryl-(CH2)x#191-oxazolidinedione and -X-heteroaryl-(CH2)X-oxazolidinedione substituents on the N atom of the indole ring, where x is 0 or 1, and -X-is a bond or -CH2-, and their thiazolidinedione analogs, are PPAR gamma agonists or partial agonists and are useful in the treatment and control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
INDOLES HAVING ANTI-DIABETIC ACTIVITY
-
Page 27-28; 32, (2010/02/06)
Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
